HER2-targeted drug study after kidney/ureter tumor surgery
Part of Cancer clinical trials.
This Phase 2 trial studies a HER2-targeted medicine (RC48-ADC) plus another drug (JS001) to help prevent cancer from coming back after surgery for upper urinary tract urothelial cancer. It may be an option if your tumor has higher HER2 levels and you have no spread to distant organs.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be at least 18 years old and willing to sign consent to join the study
- Have had radical kidney-and-ureter surgery for upper tract urothelial cancer with mostly urothelial cancer, allowing mixed urothelial/squamous features
- Your cancer must be staged with no distant spread, such as pT2–pT4 with pN0–pN2 or any T with N1–N2, and any abnormal lymph nodes must be completely removed
- Your tumor tissue test must show HER2 is 2+ or 3+ on immunohistochemistry (a lab stain test for HER2)
- Be healthy enough for study treatment (ECOG 0–2) and be able to start the first study treatment within 90 days after surgery (if chosen)
- Not have distant metastases, not have certain other tumor types (pure adenocarcinoma, pure squamous, small cell, or other variants), and not have unresected enlarged lymph nodes
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of chemotherapy (gemcitabine) and a targeted drug (Trastuzumab Rezetecan) before surgery to remove the kidney and ureter. It may help shrink the tumor and improve outcomes for people with HER2-positive upper tract urothelial cancer.
This trial tests a combination of two drugs (disitamab vedotin and tislelizumab) to treat HER2-positive high-risk upper tract urothelial cancer, aiming to save the kidney instead of removing it. The drugs target cancer cells and boost the immune system to fight the cancer.
This study tests whether combining two drugs—toripalimab (an immunotherapy that boosts your immune system) and 9MW2821 (a targeted drug that delivers treatment directly to cancer cells)—before surgery helps shrink tumors and improves outcomes for people with upper tract urothelial cancer. The goal is to see if this combination is safe and effective before the kidney and ureter are removed.
This trial tests whether combining the immunotherapy drug tislelizumab with the chemotherapy drug nab-paclitaxel before surgery can help treat high-risk upper tract urothelial cancer. The goal is to shrink the tumor and improve outcomes for patients who are planning to have their kidney and ureter removed.
This study helps doctors pick the best treatment for you after surgery for advanced upper tract urothelial cancer. It looks at your cancer details to guide whether more treatment, like chemotherapy, might help you.
This trial tests a combination of an antibody-drug conjugate (RC48) plus chemotherapy (gemcitabine) given before bladder removal surgery. It is for people with HER2-positive bladder cancer that has grown into the muscle layer.
Hear when a new Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.